Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-04-26
2011-04-26
Morris, Patricia L (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S273400
Reexamination Certificate
active
07932273
ABSTRACT:
Ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate in the crystalline modifications I and II and as the hemihydrate and the use thereof as a pharmaceutical composition.
REFERENCES:
patent: 4367217 (1983-01-01), Gruber et al.
patent: 4427648 (1984-01-01), Brickl et al.
patent: 4438091 (1984-03-01), Gruber et al.
patent: 4675405 (1987-06-01), Musser et al.
patent: 5416099 (1995-05-01), Hartman et al.
patent: 5434150 (1995-07-01), Austel et al.
patent: 5800836 (1998-09-01), Morella et al.
patent: 6087380 (2000-07-01), Hauel et al.
patent: 6414008 (2002-07-01), Hauel et al.
patent: 6469039 (2002-10-01), Hauel et al.
patent: 6627646 (2003-09-01), Bakale et al.
patent: 6710055 (2004-03-01), Hauel et al.
patent: 6900229 (2005-05-01), Hauel et al.
patent: 7189743 (2007-03-01), Hauel et al.
patent: 7202368 (2007-04-01), Zerban et al.
patent: 2003/0181488 (2003-09-01), Brauns
patent: 2005/0038077 (2005-02-01), Kohlrausch et al.
patent: 2005/0095293 (2005-05-01), Brauns et al.
patent: 2005/0107438 (2005-05-01), Radtke et al.
patent: 2006/0183779 (2006-08-01), Brauns
patent: 2006/0222640 (2006-10-01), Reilly et al.
patent: 2006/0247278 (2006-11-01), Sieger et al.
patent: 2006/0276513 (2006-12-01), Hauel et al.
patent: 2007/0105753 (2007-05-01), Eisert et al.
patent: 2007/0149589 (2007-06-01), Zerban et al.
patent: 2007/0185173 (2007-08-01), Zerban et al.
patent: 2007/0185333 (2007-08-01), Zerban et al.
patent: 19752843 (1999-07-01), None
patent: 10245624 (2004-04-01), None
patent: 0540051 (1993-05-01), None
patent: 0623596 (1994-11-01), None
patent: 0655439 (1995-05-01), None
patent: 58134033 (1983-08-01), None
patent: 9837075 (1998-08-01), None
patent: 03/007984 (2003-01-01), None
Doelker, english translation of Ann. Pharm. Fr. 2002, 60:161-176, pp. 1-39.
Singhal et al., “Drug Polymorphism, etc., ”Advanced drug delivery reviews 56, 335-347 (2004).
CMU Pharmaceutical polymorphism, Internet p. 1-3 (2002) (print out Apr. 3, 2008).
Davidovich, M., et al Detectio of Polymorphism by Powder X-Ray Diffraction: Interference by Preferred Orientation; American Pharmaceutical Review. IN: Russell Pub., 2004, 7(1) pp. 10, 12, 14, 16, and 100.
Ciara, Mino R.; Crystalline Polymorphism of Organic Compounds; Topics in Current Chemistry, 198, Berlin Heidelberg: Springer Vertag, 1998 pp. 164-208.
Berstein, Joel; Polymorphism in Molecular Crystals; Oxford: Clarendon Press, 2002, pp. 117, 118, 272 and 273.
Doelker; English Translation of S.T.P., Pharma Pratiques (1999), 9(5), 399-409, pp. 133.
Ulicky, L. and Kemp, T.J.; Comprehensive Dictionary of Physical Chemistry; NY: PTR Prentice Hall (1992) p. 21.
Haleblian, John and McCrone Walter; Pharmaceutical Applications of Polymorphism; Journal of Pharmaceutical Sciences, (1969), 58 pages 911-929.
Chemical & Engineering News, Feb. 2003, pp. 32-35.
Brittain, Harry G.; Polymorphism in Pharmaceutical Solids; NY: Marcel Dekker, Inc, 1999, pp. 1-2, 188-226.
US Pharmacopia #23, National Formulary #18 (1995) pp. 1843-1844.
Muzaffar, N.A., et al: Polymorphism and Drug Availability , Journal of Pharmacy (Lahore) 1979, 1(1), 59-66.
Jain, N. K. and Mohammed, M.N.; Polymorphism, Indian Drugs, 1986, 23 (6), pp. 316-329.
Taday, P.F., et al; Using Terahertz Pulse Spectroscopy to Study the Crystalline Structure of a Drug: A Case Study of the Polymorphs of Ranitidine Hydrochloride; Journal of Pharmaceutical Sciences, 92 (4), 2003, pp. 831-838.
Wall, G. Michael; Pharmaceutical applications of Drug Crystal Studies; Pharmaceutical Manufacturing, 1986, pp. 33-42.
Concise Encyclopedia, NY: Walter de Gruyter, 1994, pp. 872-873.
Otuska, M., et al: Effect of Polymorphic Forms of Bulk Powders on Pharmaceutical Properties of Carbamazepine Granules; Chem. Pharm. Bull. 47(6)0, pp. 852-856 (1999).
Hauel, N.H., Structure-Based Design of Novel Potent Nonpeptide Thrombin Inhibitors, J. Med. Chem. 2002, 45, 1757-1766, XP 001098844.
Nagahara, T., et al; Dbasic (Amidinoaryl) Propanoic Acid Derivatives as Novel Blood Coagulation Factor Xa Inhibitors, J. Med.,Chem. 1994, 37, pp. 1200-1207.
Mungall, Dennis, BIBR-1048 Boehringer Ingelheim, Current Opinion in Investigational Drugs, 2002 3(6) 905-907-XP001147306.
Stangier, et al; Abstract of J Thrombosis and Haemotosis, vol. I, Supplement 1, Jul. 12-18, 2003.
Gustafsson< D., Abstract of J. Intern. Med. Oct. 2003 254(4); 322-34: PMID: 12974871.
Stangier, et al; Abstract of the J. of Clinical Pharmacology, 2005; 45: 555-563.
The Merck Index 14th Edition, Merck & Co., NJ, USA, 2001, No. 9156, 4308 and 845, Ecuador, (Dec. 2006).
Berge, Stephen M., et al; Pharmaceutical Salts; Journal of Pharmaceutical Sciences (1977) vol. 66, No. 1 pp. 1-19.
Collins, Ben, et al; Antithrombotic Drug Market; Nature Review: Drug Discovery (2003) vol. 2, No. 1, pp. 11-12.
Stangier, J., et al; Pharmacokinetics of BIBR 953 W, A Novel Low molecular Weight Direct Thrombin Inhibitor in Healthy Volunteers; Supplement to the Journal Thrombosis and Haemostasis (2001) Abstract.
Schmid Rolf
Sieger Peter
Sobotta Rainer
Boehringer Ingelheim International GmbH
Morris Michael P.
Morris Patricia L
Petka Wendy A.
LandOfFree
3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2694267